Stelo by Dexcom

The release of Stelo by Dexcom marks a major shift in continuous glucose monitoring (CGM) technology, representing the first consumer-facing glucose biosensor cleared by the FDA for over-the-counter (OTC) acquisition in the United States. Designed specifically for adults aged 18 and older who have Type 2 diabetes not managed with insulin, as well as health-conscious individuals seeking metabolic clarity, Stelo bypasses traditional prescription and insurance authorization pathways. The hardware utilizes a wear-and-forget biosensor containing a flexible wire micro-filament that measures interstitial fluid glucose levels continuously over a 15-day lifespan.

The application architecture establishes a continuous Bluetooth Low Energy (BLE) pairing with the sensor, capturing interstitial glucose readings every 5 minutes and updating trend visualizations within the user interface every 15 minutes. The platform incorporates AI-driven analytics that digest glucose fluctuations alongside manual meal logs, sleep metrics, and physical activity data imported via health platform integrations. Rather than relying on high-frequency clinical alarms, Stelo synthesizes raw metabolic fluctuations into contextualized Glucose Scores and interactive trend summaries designed to correlate dietary choices directly with glycemic spikes. It can sync with Apple Health / Health Connect.

From a software engineering and clinical safety perspective, Dexcom made deliberate choices when differentiating Stelo from its medical counterpart, the Dexcom G7. Because Stelo is explicitly contra-indicated for individuals with insulin-dependent diabetes or severe hypoglycemia, the application intentionally omits real-time urgent low glucose alarms. This design decision conserves battery, streamlines the user interface, and reduces alarm fatigue, focusing instead on long-term behavioral modifications through meal response evaluation.